UBS AM’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.84B | Buy |
13,199,103
+198,289
| +2% | +$27.8M | 0.38% | 43 |
|
|
2025
Q4 | $1.6B | Buy |
13,000,814
+12,299
| +0.1% | +$1.49M | 0.34% | 52 |
|
|
2025
Q3 | $1.44B | Sell |
12,988,515
-3,594,563
| -22% | -$409M | 0.31% | 57 |
|
|
2025
Q2 | $1.84B | Buy |
16,583,078
+2,827,597
| +21% | +$301M | 0.37% | 48 |
|
|
2025
Q1 | $1.54B | Buy |
13,755,481
+1,520,809
| +12% | +$157M | 0.39% | 45 |
|
|
2024
Q4 | $1.13B | Buy |
12,234,672
+1,605,730
| +15% | +$145M | 0.26% | 67 |
|
|
2024
Q3 | $891M | Sell |
10,628,942
-510,833
| -5% | -$39M | 0.23% | 81 |
|
|
2024
Q2 | $764M | Buy |
11,139,775
+1,614,934
| +17% | +$108M | 0.22% | 81 |
|
|
2024
Q1 | $698M | Buy |
9,524,841
+78,816
| +0.8% | +$6.06M | 0.25% | 72 |
|
|
2023
Q4 | $765M | Buy |
9,446,025
+90,164
| +1% | +$7.02M | 0.3% | 61 |
|
|
2023
Q3 | $701M | Buy |
9,355,861
+450,908
| +5% | +$34.7M | 0.31% | 62 |
|
|
2023
Q2 | $739M | Hold |
8,904,953
| – | – | 0.36% | 53 |
|
|
2023
Q1 | $739M | Sell |
8,904,953
-468,432
| -5% | -$38.8M | 0.36% | 53 |
|
|
2022
Q4 | $805M | Sell |
9,373,385
-488,144
| -5% | -$38.7M | 0.42% | 43 |
|
|
2022
Q3 | $608M | Buy |
9,861,529
+646,166
| +7% | +$40.7M | 0.34% | 54 |
|
|
2022
Q2 | $570M | Sell |
9,215,363
-2,573,580
| -22% | -$159M | 0.3% | 67 |
|
|
2022
Q1 | $701M | Buy |
11,788,943
+2,527,753
| +27% | +$162M | 0.3% | 65 |
|
|
2021
Q4 | $672M | Buy |
9,261,190
+334,255
| +4% | +$23M | 0.26% | 79 |
|
|
2021
Q3 | $624M | Buy |
8,926,935
+244,381
| +3% | +$17.2M | 0.26% | 75 |
|
|
2021
Q2 | $598M | Sell |
8,682,554
-377,950
| -4% | -$25.2M | 0.26% | 75 |
|
|
2021
Q1 | $586M | Buy |
9,060,504
+63,451
| +0.7% | +$4.09M | 0.26% | 75 |
|
|
2020
Q4 | $524M | Buy |
8,997,053
+392,859
| +5% | +$23.7M | 0.25% | 80 |
|
|
2020
Q3 | $544M | Buy |
8,604,194
+349,009
| +4% | +$24.2M | 0.29% | 63 |
|
|
2020
Q2 | $635M | Buy |
8,255,185
+1,471,150
| +22% | +$113M | 0.39% | 50 |
|
|
2020
Q1 | $507M | Buy |
6,784,035
+159,122
| +2% | +$11M | 0.36% | 55 |
|
|
2019
Q4 | $430M | Buy |
6,624,913
+12,065
| +0.2% | +$786K | 0.26% | 74 |
|
|
2019
Q3 | $419M | Buy |
6,612,848
+129,795
| +2% | +$8.48M | 0.28% | 69 |
|
|
2019
Q2 | $438M | Sell |
6,483,053
-478,760
| -7% | -$31.5M | 0.31% | 62 |
|
|
2019
Q1 | $453M | Buy |
6,961,813
+850,855
| +14% | +$56.6M | 0.34% | 58 |
|
|
2018
Q4 | $382M | Buy |
6,110,958
+185,259
| +3% | +$12.9M | 0.33% | 59 |
|
|
2018
Q3 | $458M | Sell |
5,925,699
-96,705
| -2% | -$7.3M | 0.34% | 57 |
|
|
2018
Q2 | $427M | Buy |
6,022,404
+271,398
| +5% | +$19.2M | 0.33% | 57 |
|
|
2018
Q1 | $434M | Sell |
5,751,006
-199,923
| -3% | -$15.9M | 0.34% | 58 |
|
|
2017
Q4 | $426M | Sell |
5,950,929
-376,866
| -6% | -$28.6M | 0.36% | 58 |
|
|
2017
Q3 | $513M | Buy |
6,327,795
+220,813
| +4% | +$16.9M | 0.47% | 43 |
|
|
2017
Q2 | $432M | Sell |
6,106,982
-185,823
| -3% | -$12.4M | 0.42% | 47 |
|
|
2017
Q1 | $427M | Sell |
6,292,805
-599,876
| -9% | -$42.2M | 0.44% | 44 |
|
|
2016
Q4 | $494M | Sell |
6,892,681
-1,018,180
| -13% | -$75.7M | 0.55% | 31 |
|
|
2016
Q3 | $626M | Sell |
7,910,861
-885,754
| -10% | -$72M | 0.67% | 23 |
|
|
2016
Q2 | $734M | Sell |
8,796,615
-217,946
| -2% | -$19.3M | 0.83% | 15 |
|
|
2016
Q1 | $828M | Buy |
9,014,561
+368,095
| +4% | +$33.2M | 0.96% | 11 |
|
|
2015
Q4 | $875M | Sell |
8,646,466
-381,632
| -4% | -$39.7M | 1% | 11 |
|
|
2015
Q3 | $886M | Sell |
9,028,098
-635,435
| -7% | -$70.6M | 0.98% | 10 |
|
|
2015
Q2 | $1.13B | Sell |
9,663,533
-264,416
| -3% | -$28.9M | 1.08% | 6 |
|
|
2015
Q1 | $974M | Sell |
9,927,949
-423,754
| -4% | -$43M | 0.94% | 9 |
|
|
2014
Q4 | $976M | Buy |
10,351,703
+271,772
| +3% | +$28.1M | 0.93% | 8 |
|
|
2014
Q3 | $1.07B | Sell |
10,079,931
-781,937
| -7% | -$76.6M | 1.06% | 8 |
|
|
2014
Q2 | $901M | Sell |
10,861,868
-364,798
| -3% | -$28.4M | 0.91% | 10 |
|
|
2014
Q1 | $796M | Buy |
11,226,666
+996,880
| +10% | +$78.2M | 0.85% | 12 |
|
|
2013
Q4 | $769M | Sell |
10,229,786
-2,261,699
| -18% | -$157M | 0.88% | 12 |
|
|
2013
Q3 | $785M | Sell |
12,491,485
-2,048,100
| -14% | -$122M | 0.97% | 10 |
|
|
2013
Q2 | $745M | Buy |
+14,539,585
| New | +$758M | 0.96% | 12 |
|
Other funds holding GILD
VCM
VPM
UBS AM's GILD Position: Q1 2026 in Review
UBS AM increased its Gilead Sciences (GILD) stake by 1.5% in Q1 2026, buying an estimated $27.8M and bringing the position to 13,199,103 shares worth $1.84B. The position accounts for 0.38% of the portfolio, ranked #43.
UBS AM first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- UBS AM held 13,199,103 shares of Gilead Sciences worth $1.84B as of Q1 2026.
- UBS AM bought 198,289 Gilead Sciences shares in Q1 2026, an estimated $27.8M.
- Gilead Sciences made up 0.38% of UBS AM's portfolio in Q1 2026, its #43 holding.
- UBS AM first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.